CLEAR CELL ADENOCARCINOMA ARISING FROM ADENOMYOSIS MIMICKING LEIOMYOMA: A CASE REPORT

Yoo Jeong Shin, MD, Se-Eun Cho, MD, Chang Ohk Sung, MD, Chel Hun Choi, MD, Duk-Soo Bae, MD, PhD
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

The incidence of cancer from adenomyosis is rare. Previously, only two cases of clear cell adenocarcinoma (CCA) arising from adenomyosis have been reported in English literature. Here, we report a case of CCA arising from adenomyosis. A 52-year-old postmenopausal Korean woman presented with complaints of vaginal bleeding and back pain. Endometrial biopsy revealed endometrial polyp with atrophic change and transvaginal ultrasonography showed myomas with cystic change. Magnetic resonance imaging revealed a cystic degenerative mass consistent with leiomyoma in the posterior portion of uterus body. And the serum level of CA-125 was 17.7 U/mL. Hysterectomy revealed a yellow-ten solid mass in the myometrium that was diagnosed as CCA arising from adenomyosis. The tumor was mainly located in the myometrium and transition between adenomyosis and CCA along with endometrial stromal cell was identified. Malignant tumor arising from adenomyosis could be considered as a differential diagnosis when the patient with adenomyosis and intact endometrial surface complained of vaginal bleeding.

Keywords: Adenocarcinoma, clear cell; Endometriosis; Eestrogen receptor; Progesterone receptor; p53

Received: 2011. 5.24. Revised: 2011. 7. 5. Accepted: 2011. 7.22. Corresponding author: Duk-Soo Bae, MD, PhD Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Tel: +82-2-3410-3511 Fax: +82-2-3410-0630 E-mail: ds123.bae@samsung.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2011. Korean Society of Obstetrics and Gynecology
3.3 cm cystic degenerative mass consistent with leiomyoma in the posterior portion of uterine body (Fig. 1). The cystic degenerative mass was not involved endometrium and no tumor was recognized in other organs.

Preoperative differential diagnoses included leiomyoma, leiomyosarcoma, endometrial carcinoma, or endometrial stromal sarcoma. We performed a laparoscopic assisted vaginal hysterectomy and frozen section revealed clear cell adenocarcinoma. Laparoscopic bilateral salpingo-oophorectomy, pelvic lymphadenectomy, paraaortic lymphadenectomy and total omentectomy were performed as surgical staging. There was no evidence of gross dissemination. Macroscopically, the resected uterus weighed 100 g (10 × 7 cm). Cross-section of the posterior uterine wall revealed an yellow-tan solid mass, measuring 4 × 3 cm in the myometrium with pushing the endometrium (Fig. 2A). The mass was mainly located in the myometrium that was clinically suspected as mesenchymal tumor, such as leiomyoma or leiomyosarcoma, and endometrium was unremarkable. Microscopically, however, the tumor was CCA (Fig. 2B) and there was no connection between the myometrial mass and endometrium (Fig. 2C).

Interestingly periphery of the myometrial tumor showed numerous adenomyosis, which were intimacy related with tumor (Fig. 3A), and we identified that CCA arising from the adenomyosis (Fig. 3B). When we examined entirely endometrium, there was a focal isolated CCA in the endometrium (Fig. 3C). The previous reported case with CCA arising from adenomyosis showed estrogen receptor (ER), progesterone receptor (PR) and p53 expression in the tumor. In our patient, the clear cell adenocarcinoma stained positively for ER, but did not express PR and p53 protein (Fig. 3D).

Based on these findings, this case was diagnosed as being CCA, grade III, arising from adenomyosis and classified as International Federation of Gynecology and Obstetrics stage Ib because of the invasion more than half of the myometrium. Postoperatively, whole pelvis radiotherapy (total dose of 5,040 cGy) was performed to prevent local recurrence because laparoscopic assisted vaginal hysterectomy had the possibility of tumor spillage and three cycles of systemic chemotherapy (paclitaxel 175 mg/m² and carboplatin 5 AUC) were performed.

**Discussion**

The development of adenocarcinoma arising from adenomyosis...
Fig. 2. (A) Yellowish round mass in the myometrium. (B) Microscopic findings of the mass show typical morphologies of clear cell carcinoma (H&E, ×400). (C) There is no connection between the mass and endometrium (H&E, ×100).

Fig. 3. (A) Periphery of the myometrial tumor shows numerous adenomyosis (arrows), which are intimacy related with tumor (H&E, ×200). (B) Clear cell carcinoma (arrows) arising from adenomyosis (H&E, ×200). (C) There is a focal isolated clear cell carcinoma in the endometrium (H&E, ×200). (D) The tumor is negative for p53 immunohistochemistry (Immunohistochemistry, ×200).
have been rarely reported. And it is difficult to distinguish adenocarcinoma arising from adenomyosis from endometrial carcinoma arising from eutopic endometrium extend into preexisting adenomyosis [5]. In case of adenocarcinoma arising from adenomyosis, the following Sampson’s or Colman’s [6] criteria should be fulfilled to confirm the malignant transformation: 1) the carcinoma must not be located in the endometrium and elsewhere in the pelvis; 2) the carcinoma must be seen to arise from the epithelium of the adenomyosis and not to have invaded from another source; and 3) endometrial (adenomyotic) stromal cells must be present to support the diagnosis of adenomyosis. And Jacques and Lawrence [7] found a number of histologic features useful in identifying adenocarcinoma arising from adenomyosis, including a smooth, round contour of surrounding myometrium, adenomyotic glands and endometrial-type stroma within the carcinoma foci, and the absence of desmoplasia or an inflammatory response. Kumar and Anderson [8] emphasized the necessity of presence of the transition between the benign adenomyotic endometrial glands and the carcinomatous glands to prove the diagnosis of an ectopic endometrium-derived adenocarcinoma. In our case, although there was a focal isolated CCA in the endometrium, the diagnosis was compatible with CCA arising from adenomyosis because of the tumor being mainly located in the myometrium and identifying obvious transition between adenomyosis and CCA along with endometrial stromal cell.

Because of the rarity, the prognosis features of adenocarcinoma arising from adenomyosis are not well characterized. Niwa et al. [9] reported that patients with p53-overexpressing tumors also lacked ER or PR had a poor prognosis.

In summary, we report a case of clear cell adenocarcinoma arising from adenomyosis. Adenocarcinomas arising from adenomyosis are very rare and preoperative diagnosis is actually difficult. In some cases, carcinomas arising in adenomyosis may be associated with a delay in diagnosis, potentially resulting in a more advanced stage at presentation. The early diagnosis can be achieved by periodic follow-up using ultrasonography to detect any change in adenomyosis and if there is any change, MRI can be performed for further evaluation. Malignant tumor arising from adenomyosis could be considered as a differential diagnosis when the patient with adenomyosis and intact endometrial surface complained of vaginal bleeding.

References

平滑근종으로 오인된 샘근육증에서 기원한 투명세포암

성균관대학교 의과대학 산부인과학교실
신유정, 조세은, 성창옥, 최철훈, 배덕수

샘근육증에서 기원한 악성종양은 매우 드물게 발생한다. 지금까지 샘근육증에서 기원한 투명세포암은 단 두 사례가 보고되었다. 우리는 이 논문을 통해 샘근육증에서 기원한 투명세포암의 새로운 사례를 보고하고자 한다. 52세 여자 환자가 절혼혈 및 하리통증을 주소로 산부인과에 내원하였다. 자궁내막 조직검사 결과 위축성 변화를 동반한 자궁내막 용종이 진단되었고, 질식초음파와 자기공명영상에서는 남성 변화를 동반한 평활근종 소견을 보였다. CA-125의 혈중 수치는 17.7 U/mL였다. 자궁절제술을 시행하였고, 근육층의 과사된 부위에서 샘근육증에서 기원한 투명세포암이 진단되었다. 종양은 주로 근육층에 위치하고 있었고, 자궁내막 간질세포를 따라 샘근육증과 투명세포암 사이의 세포 변화를 관찰할 수 있었다. 샘근육증을 진단받은 환자에서 자궁내막에 이상 소견이 없으면서 절충혈이 발생한 경우 샘근육증에서 기원한 악성종양이 감별진단으로 고려되어야 한다.

중심단어: 투명세포암, 자궁내막증, 에스트로겐 수용체, 프로게스테론 수용체, p53